• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    OTC Markets Group Announces Quarterly Index Performance and Rebalancing

    7/20/21 4:00:00 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CMPX alert in real time by email

    NEW YORK, July 20, 2021 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX:OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced the second quarter 2021 performance and quarterly rebalancing of the OTCQX® and OTCQB® indexes, including the OTCQX Canada Index and the OTCQX Dividend Index.

    The OTCQX Composite Index (.OTCQX), a benchmark for the overall OTCQX Best Market, was up 3.9% in the second quarter. Ninety-two new companies were added to the index, including: AirBoss of America Corp. (OTCQX:ABSSF); Blackrock Silver Corp. (OTCQX:BKRRF); Belo Sun Mining Corp. (OTCQX:BSXGF); Caldwell Partners International Inc. (OTCQX:CWLPF); Graphite One Inc. (OTCQX:GPHOF) and Osprey Bitcoin Trust (OTCQX:OBTC). Forty-two were removed from the index, including Virginia National Bankshares (VABK), Largo Resources Ltd. (LGO), and Stabilis Solutions Inc. (SLNG) which graduated to NASDAQ in April. In May, New Pacific Metals Corp. (NEWP) graduated to NYSE MKT, Nouveau Monde Graphite Inc. (NMG) graduated to NYSE, and Tuesday Morning Corp (TUEM) graduated to NASDAQ. Hut 8 Mining Corp (HUT) and Better Choice Company Inc. (BTTR) graduated to NASDAQ in June.

    The OTCQX Billion+ Index (.OTCQXBIL), which tracks the performance of $1 billion-plus market cap OTCQX companies, was up 6.7% for the quarter. Ten companies were added to the index including: AKER CARBON CAPTURE ASA (OTCQX:AKCCF);DIVERSIFIED ENERGY COMPANY PLC (OTCQX:DECPF); Harvest Health & Recreation Inc. (OTCQX:HRVSF)

    Seven companies were removed.

    The OTCQX Dividend Index (.OTCQXDIV), which tracks dividend-paying U.S. and international OTCQX companies, was up 8.4% in the quarter. Thirty-three new companies were added to the index including: adidas AG (OTCQX:ADDYY); Caldwell Partners International Inc. (OTCQX:CWLPF); Hochschild Mining PLC (OTCQX:HCHDF); Turkiye Garanti Bankasi A.S. (OTCQX:TKGBY); Wal-Mart De Mexico S.A.B. de C.V. (OTCQX:WMMVY); Zurich Insurance Group Ltd (OTCQX:ZURVY). Fourteen companies were removed.

    The OTCQX Banks Index (.OTCQXBK), comprised of OTCQX community and regional banks, increased 9.2% in the second quarter. Fourteen banks were added to the index in the quarter and 10 companies were removed. The fourteen banks added were: American Riviera Bank (Santa Barbara, CA) (OTCQX:ARBV); Bank of San Francisco (OTCQX:BSFO); CNB Community Bancorp Inc. (OTCQX:CNBB); CW Bancorp (OTCQX:CWBK); ES Bancshares, Inc. (OTCQX:ESBS); GBank Financial Holdings Inc. (OTCQX:GBFH); Integrated Financial Holdings, Inc. (OTCQX:IFHI); Lumbee Guaranty Bank (OTCQX:LUMB); Lyons Bancorp, Inc. (OTCQX:LYBC); Oconee Financial Corp. (OTCQX:OSBK); PB Financial Corporation (OTCQX:PBNC); Santa Cruz County Bank (CA) (OTCQX:SCZC, l=en&, o=3234227-1&, h=3322708003&, u=https%3A%2F%2Fwww.otcmarkets.com%2Fstock%2FTYCB%2Foverview%3Futm_source%3DPress%2520release%26utm_medium%3DPress%2520release%26utm_campaign%3DQuarterly%2520Index%2520Release%26utm_term%3DQuarterly%2520Index%2520Release&, a=)))%3B+Calvin+B.+Taylor+Bankshares%2C+Inc." rel="nofollow">); Calvin B. Taylor Bankshares, Inc. (OTCQX:TYCB); Tri County Financial Group Inc. (OTCQX:TYFG).

    The OTCQX International Index (.OTCQXINT), a benchmark for international OTCQX companies, was up 7.8% for the quarter. Forty-two new companies were added to the index including: ABAXX Technologies Inc. (OTCQX:ABXXF); Brainchip Holdings Ltd. (OTCQX:BRCHF); Troilus Gold Corp. (OTCQX:CHXMF); Desert Mountain Energy Corp. (OTCQX:DMEHF); FansUnite Entertainment Inc. (OTCQX:FUNFF); Orexo AB (OTCQX:ORXOY).

    Forty-eight companies were removed.

    The OTCQX Canada Index (.OTCQXCAN), which tracks Canadian OTCQX companies, was up 4.8% in the second quarter. Fifty companies were added to the index and nineteen companies were removed.

    OTCQX U.S. Index (.OTCQXUS), a benchmark for U.S. OTCQX companies, was down 0.7% in the second quarter. Twenty-seven companies were added to the index and seventeen companies were removed.

    OTCQX Cannabis Index (.OTCQXMJ), a benchmark for cannabis companies, was down 2.1% in the second quarter. Six new companies joined the index. The six companies added were:  

    Emerald Health Therapeutics Inc. (OTCQX:EMHTF); GOODNESS GROWTH HLDGS INC. (OTCQX:GDNSF); Trulieve Cannabis Corporation (OTCQX:TCNNF); Tinley Beverage Co, Inc. (OTCQX:TNYBF); TAAT Global Alternatives Inc. (OTCQX:TOBAF) and The Valens Company Inc. (OTCQX:VLNCF). Six companies were removed.

    The OTCQB Venture Index (.OTCQB), which tracks the overall OTCQB Venture Market, was down 8.4% in the second quarter. Two hundred-eleven companies were added to the index including: Aurelius Minerals Inc. (OTCQB:AURQF); Brazil Minerals, Inc. (OTCQB:BMIX); Compass Therapeutics, Inc. (OTCQB:CMPX); Deep Green Waste & Recycling, Inc. (OTCQB:DGWR); HealthWarehouse.com, Inc. (OTCQB:HEWA); RegeneRx Biopharmaceuticals, Inc. (OTCQB:RGRX) and Stevens Gold Nevada Inc. (OTCQB:STVGF). Ninety-two companies were removed. 

    For a list of all index additions and deletions, visit

    https://www.otcmarkets.com/files/Quarterly_Index_Constituent_Changes.pdf

    All indexes are market capitalization-weighted and adjusted on a quarterly basis for additions and share changes over 5% during the months of March, June, September and December. In the case of ADRs, the DR ratio is considered. Dividends are re-invested as of the close of business the day before the ex-dividend date.

    The OTCQX Composite Index, OTCQX Billion+ Index, OTCQX Dividend Index, OTCQX International Index, OTCQX U.S. Index, OTCQX Banks Index, OTCQX Cannabis Index, and OTCQB Venture Index have minimum liquidity screens to ensure tradability. 

    All index data is priced in real-time and is available on the OTC Markets Group website, www.otcmarkets.com, and via major financial data distributors and websites, including Bloomberg, Reuters and FT.com. 

    Past performance does not guarantee future results. Investors cannot invest directly in any of these indexes.   

    OTC Markets Group Inc. provides no advice, recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

    About OTC Markets Group Inc.

    OTC Markets Group Inc. (OTCQX:OTCM) operates the OTCQX® Best Market, the OTCQB® Venture Market and the Pink® Open Market for 11,000 U.S. and global securities. Through OTC Link® ATS and OTC Link ECN, we connect a diverse network of broker-dealers that provide liquidity and execution services. We enable investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors.

    To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.

    OTC Link ATS and OTC Link ECN are SEC regulated ATSs, operated by OTC Link LLC, member FINRA/SIPC.

    Subscribe to the OTC Markets RSS Feed

    Media Contact:

    OTC Markets Group Inc., +1 (212) 896-4428, [email protected]

    (PRNewsfoto/OTC Markets Group Inc.)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/otc-markets-group-announces-quarterly-index-performance-and-rebalancing-301337881.html

    SOURCE OTC Markets Group Inc.

    Get the next $CMPX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CMPX

    DatePrice TargetRatingAnalyst
    7/1/2025$9.00Outperform
    Raymond James
    4/2/2025$6.00Market Perform → Outperform
    Leerink Partners
    2/24/2025$12.00Buy
    Guggenheim
    2/19/2025$12.00Overweight
    Piper Sandler
    12/23/2024$32.00Buy
    D. Boral Capital
    11/15/2024$5.00 → $4.00Outperform → Market Perform
    Leerink Partners
    9/16/2024$5.00Neutral → Buy
    Ladenburg Thalmann
    1/31/2023$8.00Buy
    Jefferies
    More analyst ratings

    $CMPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Schuetz Thomas J. bought $21,100 worth of shares (10,000 units at $2.11), increasing direct ownership by 0.15% to 6,480,825 units (SEC Form 4)

    4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

    5/27/25 3:24:21 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Gordon Carl L sold $5,678,571 worth of shares (3,571,428 units at $1.59) (SEC Form 4)

    4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

    4/11/25 7:37:43 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Orbimed Advisors Llc sold $5,678,571 worth of shares (3,571,428 units at $1.59) (SEC Form 4)

    4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

    4/11/25 7:24:24 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CMPX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James resumed coverage on Compass Therapeutics with a new price target

    Raymond James resumed coverage of Compass Therapeutics with a rating of Outperform and set a new price target of $9.00

    7/1/25 8:17:42 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Compass Therapeutics upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Compass Therapeutics from Market Perform to Outperform and set a new price target of $6.00

    4/2/25 8:43:28 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on Compass Therapeutics with a new price target

    Guggenheim initiated coverage of Compass Therapeutics with a rating of Buy and set a new price target of $12.00

    2/24/25 7:07:23 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CMPX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Schuetz Thomas J. bought $21,100 worth of shares (10,000 units at $2.11), increasing direct ownership by 0.15% to 6,480,825 units (SEC Form 4)

    4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

    5/27/25 3:24:21 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gen Counsel & Corporate Sec Anderman Jonathan bought $30,800 worth of shares (20,000 units at $1.54), increasing direct ownership by 2,000% to 21,000 units (SEC Form 4)

    4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

    4/8/25 9:30:55 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CHIEF ACCOUNTING OFFICER Lerner Neil bought $28,400 worth of shares (20,000 units at $1.42), increasing direct ownership by 7% to 320,000 units (SEC Form 4)

    4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

    4/8/25 9:25:57 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CMPX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Compass Therapeutics Inc.

    SCHEDULE 13D/A - Compass Therapeutics, Inc. (0001738021) (Subject)

    8/15/25 5:28:04 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Compass Therapeutics Inc.

    SCHEDULE 13G/A - Compass Therapeutics, Inc. (0001738021) (Subject)

    8/14/25 4:15:07 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Compass Therapeutics Inc.

    SCHEDULE 13G/A - Compass Therapeutics, Inc. (0001738021) (Subject)

    8/14/25 10:49:59 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CMPX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering

    BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. ("Compass") (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the pricing of an underwritten public offering of 33,290,000 shares of its common stock at a price to the public of $3.00 per share and pre-funded warrants to purchase up to an aggregate of 6,710,000 shares of its common stock at a price to the public of $2.9999 per pre-funded warrant to purchase one share of the common stock, which represents the per share public offering price for the common stock less the $0.0001 per share exercise p

    8/12/25 10:28:04 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Compass Therapeutics Announces Proposed Public Offering

    BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. ("Compass") (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the launch of an underwritten public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Compass. Compass also intends to grant the underwriters a 30-day option to purchase additional shares of its common stock offered in the public offering under the sam

    8/12/25 4:01:00 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update

    In the ongoing Phase 2/3 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer, fewer deaths have been observed than originally projected. We believe this may suggest that tovecimig could be affecting overall survival in the patient population. As a result, the analysis of the secondary endpoints, including overall survival, is now expected in Q1 2026.In the ongoing Phase 1 dose-escalation study of CTX-8371 (PD-1 x PD-L1 bispecific antibody) in patients treated in the post-checkpoint inhibitor setting, two deep and confirmed partial responses have been observed to date. A patient with non-small cell lung cancer had a 100% reduction in target le

    8/11/25 7:00:00 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CMPX
    Leadership Updates

    Live Leadership Updates

    View All

    Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer

    BOSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the appointment of Barry Shin as Chief Financial Officer, as of December 9, 2024. Mr. Shin is a veteran biopharmaceutical leader with over 20 years of experience as a finance and operations executive, investment banker, and corporate advisor. "We are delighted to welcome Barry to Compass during this pivotal and exciting time for the company," said Thomas Schuetz, MD, PhD, CEO of Compass and Vice Chairman of the Board of Directors. "We have severa

    12/10/24 8:00:00 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Compass Therapeutics Announces CEO Transition

    BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its Board of Directors has appointed Thomas Schuetz, M.D., Ph.D., President of Research and Development and Vice Chair of the Board of Directors of the Company, as President and Chief Executive Officer of the Company, effective May 28, 2024. Vered Bisker-Leib, Ph.D., M.B.A., has stepped down as Chief Executive Officer and as a member of the Board of Directors of the Company, effective May 28, 2024. Dr. Bisker-Leib will continue to be available

    5/28/24 4:10:20 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

    Initiated patient enrollment in a U.S. Phase 2/3 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced biliary tract cancers (BTC). Top line data is expected in the first half of 2024Continue to enroll in a U.S. Phase 2 study of CTX-009 in patients with advanced colorectal cancer (CRC). Initial data expected in the third quarter of 2023Presented results of a Phase 2 study of CTX-009 in combination with paclitaxel in patients with BTC at the 2023 ASCO GI Cancers SymposiumExpanded the management team with the appointment of Minori Rosales, M.D. PhD, as Senior Vice President & Head of Clinical DevelopmentAppointed Richard Lindahl, M.B.A., EVP & CFO of Emergent BioSolutio

    5/4/23 8:30:00 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CMPX
    Financials

    Live finance-specific insights

    View All

    Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update

    In the ongoing Phase 2/3 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer, fewer deaths have been observed than originally projected. We believe this may suggest that tovecimig could be affecting overall survival in the patient population. As a result, the analysis of the secondary endpoints, including overall survival, is now expected in Q1 2026.In the ongoing Phase 1 dose-escalation study of CTX-8371 (PD-1 x PD-L1 bispecific antibody) in patients treated in the post-checkpoint inhibitor setting, two deep and confirmed partial responses have been observed to date. A patient with non-small cell lung cancer had a 100% reduction in target le

    8/11/25 7:00:00 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025

    BOSTON, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, will release its financial results for the quarter ended June 30, 2025 and host a webcast and conference call to provide an update on the ongoing tovecimig Phase 2/3 study, clinical data for CTX-8371 and preclinical data for CTX-10726, on Monday, August 11, 2025, at 8:00 a.m. ET. Call Details: Date: Monday, August 11, 2025 Time: 8:00 AM ET Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1727543&tp_key=955a2c2f4d Dial-In: 1-877-407-9716 (US), 1-201-493-6779 (International), 13754954 (Co

    8/8/25 4:01:00 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Compass Therapeutics to Host Conference Call Highlighting Clinical Data from CTX-009

    Call scheduled for Wednesday, May 4, 2022 at 8:00 a.m. ET Key Opinion Leader to Participate BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that it will host a webinar on Wednesday, May 4, 2022 at 8:00 a.m. ET to review clinical data from its ongoing Phase 2 clinical trial assessing CTX-009. A Key Opinion Leader will join management for the discussion. Webinar Details:   Date:  May 04, 2022   Time: 8:00 a.m. ET   Webcast: Registration Link   Replay availability: A replay will be available on the Compass website for 6 months. Abo

    5/3/22 4:01:00 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CMPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Compass Therapeutics Inc.

    SC 13G/A - Compass Therapeutics, Inc. (0001738021) (Subject)

    11/14/24 10:00:35 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Compass Therapeutics Inc.

    SC 13G - Compass Therapeutics, Inc. (0001738021) (Subject)

    8/2/24 4:15:57 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Compass Therapeutics Inc. (Amendment)

    SC 13D/A - Compass Therapeutics, Inc. (0001738021) (Subject)

    3/22/24 4:59:51 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care